Welcome to our dedicated page for IONIS PHARMACEUTICALS SEC filings (Ticker: IONS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on IONIS PHARMACEUTICALS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into IONIS PHARMACEUTICALS's regulatory disclosures and financial reporting.
C. Frank Bennett, EVP and Chief Scientific Officer of Ionis Pharmaceuticals (IONS), reported an employee stock purchase on 08/29/2025. The filing shows 213 shares of Ionis common stock were acquired at a price of $27.71 under the company’s Amended and Restated 2000 Employee Stock Purchase Plan. Following the transaction the filing lists 93,679 shares beneficially owned (direct). The purchased shares are subject to a sale restriction and may not be sold until March 2, 2026. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Bennett on 09/03/2025.
Brian Birchler, EVP of Corporate and Development Operations at Ionis Pharmaceuticals (IONS), reported an insider purchase of 56,826 shares of Ionis common stock on 08/29/2025 at a price of $27.71 per share. The filing indicates these shares were acquired under the company’s Amended and Restated 2000 Employee Stock Purchase Plan and may not be sold until March 2, 2026. The Form 4 was executed by an attorney-in-fact and reflects that the shares are directly beneficially owned following the transaction.
Form 144 filed for Ionis Pharmaceuticals (IONS) reports a proposed sale of 16,000 shares of common stock via Stifel Nicolaus with an aggregate market value of $962,371.00. The filing lists approximately 159,391,229 shares outstanding and an approximate sale date of 09/03/2025 on Nasdaq. The shares were acquired by option exercise on 07/01/2016 and the proposed payment method is cash. The filer reports no securities sold in the past three months.
Ionis Pharmaceuticals (IONS) reported a Form 144 notice for a proposed sale of 124,850 shares of common stock to be handled by Stifel Nicolaus & Company, Inc. on 09/03/2025 on Nasdaq with an aggregate market value of $7,634,553.00. The shares were acquired on 01/04/2021 through an option exercise from the issuer and the planned consideration is cash. The filing also discloses a recent sale by Patrick O'Neil of 13,050 shares on 09/02/2025 for gross proceeds of $711,418.00. The filing includes the statutorily required declaration that the seller is not aware of undisclosed material adverse information.
Ionis Pharmaceuticals Form 144 notice: A proposed sale of 51,800 shares of common stock is reported to be executed through Stifel Nicolaus & Company, Inc. on 09/03/2025 with an aggregate market value of $3,152,698.00. The filing lists total shares outstanding of 159,391,229. Acquisition details for the shares to be sold are disclosed: 46,800 were acquired by option exercise on 01/03/2022, 7,537 were restricted stock units dated 01/15/2017, and 6,373 were restricted stock units dated 01/15/2016. The filing also reports sales by Frank Bennett in the past three months: 10,000 shares on 08/18/2025 for $439,776.00, and two sales on 09/02/2025 of 2,374 (proceeds $116,658.00) and 2,626 (proceeds $129,042.00). The filer signs a standard representation that no material nonpublic information is known. Other issuer contact and relationship fields are not populated in the provided content.
Ionis Pharmaceuticals (IONS) submitted a Form 144 notifying the proposed sale of 45,000 shares of common stock through Stifel Nicolaus & Company, with an aggregate market value of $2,658,996.00. The filing lists 159,391,229 shares outstanding and names Nasdaq as the exchange with an approximate sale date of 09/03/2025.
The securities were acquired by the seller on 01/31/2022 via an option exercise for 60,000 shares. The planned method of payment on sale is cash. The filing reports no securities sold by the person in the past three months and contains the standard attestation about absence of undisclosed material adverse information.
Form 144 filed for Ionis Pharmaceuticals (IONS) reports a proposed sale of common stock. The broker listed is Stifel Nicolaus & Company. The notice covers 203,814 shares with an aggregate market value of $12,230,307, to be sold approximately on 09/03/2025 on Nasdaq. The filer shows prior option-exercise acquisitions: 101,489 shares on 01/03/2022, 42,030 shares on 01/03/2023 and 102,900 shares on 01/01/2019, with payment in cash. Two small open-market sales by Brett Monia in July 2025 are also disclosed.
Ionis Pharmaceuticals (IONS) filed a Form 144 notifying a proposed sale of 3,162 shares of common stock to be executed through Stifel Nicolaus & Company on 09/03/2025. The filing reports an aggregate market value of $192,958.00 based on total shares outstanding of 159,391,229. The shares were acquired by option exercise: 928 shares on 01/03/2022 and 2,234 shares on 01/03/2023, with cash payment noted on the planned sale date. The filing includes the standard seller representation that no material nonpublic information is known to the selling person and indicates no securities sold in the past three months.
Ionis Pharmaceuticals (IONS) Form 144 notice reports a proposed sale of 19,658 shares of common stock to be executed through Stifel Nicolaus on 09/03/2025 with an aggregate market value of $1,195,421.00. The shares represent part of an award acquired on 01/02/2019 by option exercise; the planned proceeds will be received in cash.
The filing lists total outstanding shares of 159,391,229 for the issuer and discloses recent sales by the same person on 08/04/2025 of 7,095 and 2,454 shares generating gross proceeds of $303,074.00 and $105,627.00 respectively. The filer affirms no undisclosed material adverse information and provides a broker name and address for execution.
Notice of proposed sale under Rule 144: The filing reports the proposed sale of 28,000 common shares, acquired the same day by exercise of stock options and paid in cash. The broker named is UBS Financial Services, Inc. (11 Madison Avenue, New York). The aggregate market value of the shares is listed as $1,680,000.00, with 159,391,229 shares outstanding and an approximate sale date of 09/03/2024 on NASDAQ. The filer reports no securities sold in the past three months and includes the standard signature representation re: material nonpublic information and Rule 10b5-1 plan language.